Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TC Biopharm (Holdings) ( (TCBPY) ) has shared an announcement.
On October 2, 2025, TC BioPharm Limited, a subsidiary of TC BioPharm (Holdings) plc, entered administration with Michael Magnay and Rob Croxen of Alvarez and Marsal Europe LLP appointed as joint administrators. They are exploring options for the sale of the business and assets, including intellectual property and R&D assets, to benefit creditors. Despite this development, TC BioPharm (Holdings) plc continues its operations unaffected by the administration process, maintaining its industry positioning and commitment to its stakeholders.
The most recent analyst rating on (TCBPY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on TC Biopharm (Holdings) stock, see the TCBPY Stock Forecast page.
Spark’s Take on TCBPY Stock
According to Spark, TipRanks’ AI Analyst, TCBPY is a Underperform.
TC Biopharm’s overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock’s financial instability and operational inefficiencies are major concerns.
To see Spark’s full report on TCBPY stock, click here.
More about TC Biopharm (Holdings)
TC BioPharm (Holdings) plc operates in the biotechnology industry, focusing on developing innovative cell-based therapies. The company is known for its research and development in immunotherapy and has a market focus on advancing treatments for cancer and infectious diseases.
Average Trading Volume: 7,685
Technical Sentiment Signal: Sell
Current Market Cap: $141.6K
See more data about TCBPY stock on TipRanks’ Stock Analysis page.